FOLH1 and neoplasm: SUVmean, a semiquantitative PET parameter, reflects the average tracer uptake in PSMA-expressing tumor cells and is an indicator of their metabolic activity [16]. Studies have consistently shown that patients with a higher baseline SUVmean in PSMA-PET/CT imaging tend to respond better to 177Lu-PSMA therapy, likely due to increased PSMA expression in more metabolically active tumor regions, allowing for more efficient radioligand binding and targeted radiation [15].